Maintenance Venetoclax in AML Fit Patients

ConditionAcute Myeloid Leukaemia (AML)

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-60

SponsorSohag University

About this trial

this study will explore the efficacy of maintenance SC cytarabine + venetoclax therapy as regard disease free survival (DFS) in AML fit patients who achieved CR after highly aggressive chemotherapy as bridge for BMT or if BMT will be delayed or canceled due to any other reason.

Eligibility criteria

Qualifiers

Age : 18 - 60 years . Patients who are not eligible for immediate bone marrow transplantation. Newly diagnosed AML patients who attained CR after 1st line. Refractory / recurrant AML patients who attained CR after 2nd line .

Disqualifiers

Patients not on CR . Age : younger than 18 or older than 60 . Patients not eligible for bone marrow transplation

Trial design

Treatments tested in this trial

SC cytarabine +Venetoclax

Treatment groups

80 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Sohag University

Lead sponsor

Source ClinicalTrials.gov